Barclays
IART icon

Barclays’s Integra LifeSciences IART Stock Holding History

Barclays’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-245,100
Closed -$16.8M – 4404
2021
Q3 		$16.8M Buy
+245,100
New +$17.3M 0.01% 959
2021
Q2 		– Sell
-165,400
Closed -$11.4M – 4951
2021
Q1 		$11.4M Buy
+165,400
New +$11.2M 0.01% 1030
2017
Q1 		– Sell
-2,200
Closed -$94K – 6847
2016
Q4 		$94K Buy
+2,200
New +$89.4K ﹤0.01% 4793

Other funds holding IART

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Barclays's IART Position: Q2 2026 in Review

Barclays increased its Integra LifeSciences (IART) stake by 38% in Q2 2026, buying an estimated $67.8K and bringing the position to 17,647 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #3467.

Barclays first reported a position in IART in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.07M in Q4 2022. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

  • Barclays held 17,647 shares of Integra LifeSciences worth $317K as of Q2 2026.
  • Barclays bought 4,851 Integra LifeSciences shares in Q2 2026, an estimated $67.8K.
  • Integra LifeSciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3467 holding.
  • Barclays first reported a position in Integra LifeSciences in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Integra LifeSciences position peaked at $6.07M in Q4 2022.
  • 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.